Clinton Enos
Dermatology · Norfolk, VANPI 1366896458
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,823 of the $3,230 with a category attached, or 87.4%. 5 manufacturers reported payments, led by UCB, Inc. at 50.2% of the total. Reporting peaked in 2021 at $2,841 and has fallen 91.2% since, to $249 in 2025.
Across 8 payments — averaging $403.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Amgen$1K
- AbbVie$157
- Galderma Laboratories, L.p.$133
- Pfizer$15
Across 7 payments — averaging $8291.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$58K
What the payments were for
- Consulting fees$2,82387%
- Food & beverage$39212%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 1 | $1,623 |
| Amgen | 2 | $1,302 |
| AbbVie | 3 | $157 |
| Galderma Laboratories, L.p. | 1 | $133 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,230 in reported general payments places this provider in the 60th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 42 | $567,823 |
| Humira(Cf) PenAdalimumab | 34 | $452,652 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $227,836 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 25 | $194,435 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $91,130 |
| Dupixent PenDupilumab | 18 | $77,031 |
| Doxycycline Monohydrate | 20 | $788 |
| Ketoconazole | 14 | $229 |
| Triamcinolone Acetonide | 20 | $182 |
| Sodium Chloride0.9 % Sodium Chloride | 30 | $177 |
| Hydrocortisone | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Norfolk
- Jonathan SchreiberNorfolk$330K
- David PariserNorfolk$261K
- Abby van VoorheesNorfolk$64K
- Molly SmithNorfolk$11K
- Robert PariserNorfolk$10K
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
- Diego DasilvaVirginia Beach$1.1M
- Vishal PatelLeesburg$719K
- Cyndi Torosky TommasoVirginia Beach$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.